Eli Lilly and (LLY) 424B2 Prospectus for primary offering

0000059478424B2EX-FILING FEES0.999190.997810.999680.995100.999660 0000059478 2024-08-13 2024-08-13 0000059478 1 2024-08-13 2024-08-13 0000059478 2 2024-08-13 2024-08-13 0000059478 3 2024-08-13 2024-08-13 0000059478 4 2024-08-13 2024-08-13 0000059478 5 2024-08-13 2024-08-13 iso4217:USD xbrli:pure xbrli:shares

Exhibit 107

Calculation of Filing Fee Tables

(1)

424(b)(2)

(Form Type)

Eli Lilly and Company

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial effective date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be Paid

Debt

4.150% notes due 2027

Rule 457(r)

$750,000,000

99.919 %

$749,392,500

0.00014760

$110,610.33

Debt

4.200% notes due 2029

Rule 457(r)

$1,000,000,000

99.781 %

$997,810,000

0.00014760

$147,276.76

Debt

4.600% notes due 2034

Rule 457(r)

$1,250,000,000

99.968 %

$1,249,600,000

0.00014760

$184,440.96

Debt

5.050% notes due 2054

Rule 457(r)

$1,250,000,000

99.510 %

$1,243,875,000

0.00014760

$183,595.95

Debt

5.200% notes due 2064

Rule 457(r)

$750,000,000

99.966 %

$749,745,000

0.00014760

$110,662.36

Fees Previously Paid

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Carry Forward Securities

Carry Forward Securities

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Total Offering Amounts

$4,990,422,500

$736,586.36

Total Fees Previously Paid

N/A

Total Fee Offsets

N/A

Net Fee Due

$736,586.36

(1) These “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in Eli Lilly and Company’s Registration Statement on Form S-3 (File No. 333-262943), which was filed on February 24, 2022, in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering.